Novo Nordisk , the maker of blockbuster weight-loss drug Wegovy, said on Wednesday it will cut 9,000 jobs in a bid to ...

While Pfizer's market cap and dividends are at risk, Novo has a strong competitive position in GLP-1 TAM. Read why I prefer ...

The Danish drugmaker said it needed to streamline operations and become more agile, as it faces a more competitive and ...

Wegovy-maker Novo Nordisk said on Thursday it had told all its staff to return to the office as the drugmaker's new CEO tries ...

Novo Nordisk leads globally in GLP-1s despite U.S. pressure, with a strong pipeline, cost cuts, and attractive valuation.

If you’re eyeing Novo Nordisk stock right now, you’re not alone. Investors have been left scratching their heads as to what comes next, after several twists in the company’s share price. In the past ...